Grant · BBSRC
ILC Therapeutics: Optimization of synthetic IFNA14-derivatives for the development of new immunotherapy products
Partner in a Bbsrc-funded project, "Optimization of synthetic IFNA14-derivatives for the development of new immunotherapy products".
- Company
- ILC Therapeutics
- Funder
- BBSRC
- Programme
- Studentship
- Role
- Partner
- Dated
- 1 Jan 2021
- Record
- UKRI Gateway to Research
Scottish tech in one email,
every Monday.